Vyant Bio, Inc. financial data

Symbol
VYNT on OTC
Location
2370 State Route 70 West, Suite 310, Cherry Hill,, New Jersey
State of incorporation
Delaware
Fiscal year end
December 31
Former names
CANCER GENETICS, INC (to 3/31/2021), CANCER GENETICS INC (to 11/1/2010)

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 238 % -53.8%
Quick Ratio 4.16 % -47.2%
Debt-to-equity 55.1 % +357%
Return On Equity -144 % -86.4%
Return On Assets -93 % -34.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 6.27M shares -78.4%
Common Stock, Shares, Outstanding 5.92M shares +2.14%
Entity Public Float 24.7M USD -69.4%
Common Stock, Value, Issued 1K USD 0%
Weighted Average Number of Shares Outstanding, Basic 5.87M shares +29.7%
Weighted Average Number of Shares Outstanding, Diluted 5.87M shares +29.7%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 666K USD -42%
Research and Development Expense 6.77M USD +58.5%
Selling and Marketing Expense 8.8M USD +4.44%
Operating Income (Loss) -15.9M USD -1.31%
Nonoperating Income (Expense) 105K USD
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -15.8M USD +14.9%
Net Income (Loss) Attributable to Parent -22.7M USD +44.5%
Earnings Per Share, Basic -3.87 USD/shares +57.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 10M USD -51.3%
Inventory, Net 53K USD -88.8%
Assets, Current 11.5M USD -50.4%
Property, Plant and Equipment, Net 1.11M USD +8.43%
Operating Lease, Right-of-Use Asset 1.54M USD +129%
Assets 15.2M USD -59.6%
Accounts Payable, Current 655K USD -11.5%
Accrued Liabilities, Current 1.15M USD +51%
Contract with Customer, Liability, Current 72K USD -2.7%
Liabilities, Current 3.67M USD -32.5%
Operating Lease, Liability, Noncurrent 1.3M USD +152%
Liabilities 5.3M USD -16.5%
Accumulated Other Comprehensive Income (Loss), Net of Tax -32K USD +56.8%
Retained Earnings (Accumulated Deficit) -102M USD -28.8%
Stockholders' Equity Attributable to Parent 9.91M USD -68.3%
Liabilities and Equity 15.2M USD -59.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -13.7M USD +19.5%
Net Cash Provided by (Used in) Financing Activities -149K USD -102%
Net Cash Provided by (Used in) Investing Activities 3.26M USD -89%
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 5.92M shares +2.14%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -10.6M USD -153%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 16.4M USD -50.3%
Interest Paid, Excluding Capitalized Interest, Operating Activities 34K USD +325%
Deferred Tax Assets, Valuation Allowance 25.6M USD +17.5%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure
Deferred Tax Assets, Gross 26M USD +18.3%
Operating Lease, Liability 1.61M USD +134%
Depreciation 522K USD -5.09%
Payments to Acquire Property, Plant, and Equipment 617K USD +15.3%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -22.6M USD +44.7%
Lessee, Operating Lease, Liability, to be Paid 1.94M USD +123%
Property, Plant and Equipment, Gross 3.58M USD +19.7%
Operating Lease, Liability, Current 313K USD +79.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two 423K USD +169%
Lessee, Operating Lease, Liability, to be Paid, Year One 433K USD +89.9%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure -20.2%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 325K USD +80.6%
Lessee, Operating Lease, Liability, to be Paid, Year Three 427K USD +214%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 9.76M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 441K USD +237%
Operating Lease, Payments 265K USD -47.9%
Additional Paid in Capital 111M USD +1.15%
Preferred Stock, Shares Outstanding 0 shares
Amortization of Intangible Assets 0 USD -100%
Deferred Tax Assets, Net of Valuation Allowance 401K USD +120%
Share-based Payment Arrangement, Expense 1.19M USD +18.2%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%